Drug profile · INN
imatinib
ARX-IMATINIB
imatinib (ARX-IMATINIB) is a tyrosine-protein kinase abl inhibitor. Associated with Alphapharm Pty Ltd.
EMA: approved TGA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01EA01
Patents linked 2
Pipeline programs 22
News articles 1
Drug details — imatinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 2
- Programs
- 22
- Data quality
- 0.89
Quick answer
imatinib (ARX-IMATINIB) is a tyrosine-protein kinase abl inhibitor. Associated with Alphapharm Pty Ltd.
Key facts
INN imatinib
Brand ARX-IMATINIB
Mechanism Tyrosine-protein kinase ABL inhibitor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EA01
Originator Alphapharm Pty Ltd
Mechanism of action
Tyrosine-protein kinase ABL inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is imatinib?
imatinib (ARX-IMATINIB) is a tyrosine-protein kinase abl inhibitor. Associated with Alphapharm Pty Ltd.
What is the brand name for imatinib?
ARX-IMATINIB is a marketed brand name for imatinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.